Institut Pasteur

New York University

Other

Centre Nationale De La Recherche Scientifique

Institute Pasteur

Faridabano Nato

Shirley Longacre

Charles W Roth

John W Barnwell

Ronald Perraut

Hannah Polson

Shirley Longacre-Andre

Kamini Mendis

Stratis Avrameas

Therese Ternynck

Thierry Fontaine

Alexandre Avrameas

Gerard Buttin

Sarah Bonnet

Charles c/o Agnès Rimond Roth

Accordingly, the invention provides constructs in which the nucleic acids encodingMSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.

[object Object]

The present invention relates to a purified polypeptide comprising or consisting of a C-terminus Merozoite Surface Protein 1 (MSP1) antigen fromcarrying a Glycosyl-phosphatidyl-inositol group (GPI), an immunogenic composition and a vaccine against ainfection comprising said purified polypeptide.

The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of thetype, particularly, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.

The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of thetype, particularlywhich is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.

Recombinant protein containing a C-terminal fragment of plasmodium MSP-1

A product for coupling a biologically active principle with an immunovector, characterized in that the immunovector is capable of enabling the biologically active principle to be internalized into eukaryotic cells, and in that said immunovector has an affinity for the cell DNA to such an extent that it can transfer the biologically active principle into or to the immediate vicinity of the cell nuclei.

Immunovectors for the intracellular and intranuclear transport

Growing community of inventors

Antony, France

Faridabano Nato